• FDA-listed TendMIN™ system enables percutaneous Achilles tendon repair through a 1 cm incision, designed to help reduce infection risk and accelerate patient recovery.
• Fifty (50) clinical procedures performed across 15 U.S. hospitals and surgical centers, including multiple academic teaching institutions, within 4 months of pilot launch.
• Aztron is actively expanding surgeon training programs and clinical data initiatives to position TendMIN™ as a leading option in minimally invasive Achilles repair.

Aztron Medtech, a privately held orthopedic device company, today announced the completion of the 50th clinical case in the United States utilizing its TendMIN™ percutaneous Achilles tendon repair system.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828907942/en/

Dr. David Garras completed the 50th minimally invasive Achilles tendon repair using the Aztron Medtech TendMIN™ system.

The 50th procedure was performed by Dr. David Garras, a board-certified foot and ankle surgeon who has been instrumental in the clinical integration of the TendMIN™ system. "It is my pleasure to continue offering this advanced procedure to my patients," said Dr. Garras. "The TendMIN™ system enables me to perform a robust Achilles tendon repair through an incision of approximately 1 centimeter. This dramatically reduces soft tissue disruption and infection risk, while maintaining the mechanical strength required for early mobilization.”

TendMIN™ is a proprietary suture-passing and retrieval system designed to preserve soft tissue and enable patient-specific tendon suture placement through a minimally invasive incision of 1 centimeter or less. Published literature on percutaneous Achilles repair techniques has shown these approaches can reduce soft tissue complications, lower infection risk, accelerate recovery, and improve patient-reported outcomes compared to traditional open repair. (Wang et al., 2012, Wang et al., 2024)

The first 50 TendMIN pilot procedures have been performed across 15 hospitals and surgical centers in the U.S., including multiple academic teaching institutions, underscoring the strong adoption of the technology. To build on this momentum, Aztron Medtech is expanding its U.S. footprint through partnerships with leading foot and ankle, sports medicine and orthopedic distribution specialists. The company is also supporting ongoing clinical data collection and surgeon training programs.

With more than 80,000 Achilles tendon ruptures occurring annually in the U.S., Aztron envisions TendMIN™ becoming a leading minimally invasive option for patients, designed to support faster recovery and lower complication rates.

"We are excited by the early results of our pilot,” said Ben (Yi-Hsi) Huang, CEO of Aztron Medtech. “Reaching this milestone reinforces our mission to advance percutaneous Achilles tendon repair by delivering innovative solutions with the goal of improving patient safety, accelerating recovery, and enhancing clinical efficiency. We look forward to building on this momentum as we expand our U.S. platform and continue innovating toward the future of Achilles tendon repair.”

About Aztron Medtech

Aztron Medtech is a privately held orthopedic device company developing innovative solutions for advancing percutaneous Achilles tendon repair. Its flagship product, TendMIN™, received FDA listing in 2025 and leverages advanced suture-passing and retrieval technology to enable quick, minimally invasive Achilles repair through incisions 1 centimeter or less. The platform is designed to help reduce surgical complications while providing robust repair constructs that enable accelerated recovery compared to traditional open procedures. Aztron is building a broader platform to support sports medicine and foot and ankle surgery, with a focus on improving clinical outcomes, reducing infection risks, and streamlining surgical workflows. For more information, please visit Aztron Medtech website.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250828907942/en/